Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-β-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women

Hatav Ghasemi-Tehrani; M.D.¹, Arezoo Sadeghian; M.D.², Reza Entezari; M.D.²

¹ Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
² Students’ Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Received July 2017; Revised and accepted December 2017

Abstract

Objective: To evaluate the relationship between maternal serum levels of pregnancy-associated-plasma-protein-A (PAPP-A) and β-human-chorionic-gonadotropin (β-hCG) and pregnancy complications.

Materials and methods: This is a case-control study conducted during 2015-2016. Women at their first pregnancy were enrolled and serum PAPP-A and free-β-hCG were measured in 9-14 weeks of gestation. They were followed till the end of pregnancy looking for complications including preterm labor, pregnancy induced hypertension (PIH), abortion, and intra-uterine growth retardation (IUGR).

Results: A total of 1070 pregnant women (mean age: 28.64 ± 4.95 years) were enrolled. Low serum levels of PAPP-A were more frequent in patients developing IUGR (17.4% versus 1.2%, p < 0.001), preterm labor (13% versus 2%, p = 0.013), and PIH (17.4% versus 4%, p = 0.015) compared those without complications. The serum levels of free-β-hCG were not different in patients with and without complications (p > 0.05).

Conclusion: There is an association between low serum levels of PAPP-A and developing IUGR, preterm labor, and PIH.

Keywords: β-hCG; Complications; First Trimester; PAPP-A; Pregnancy

Introduction

Today, one of the most effective methods for screening chromosomal abnormalities during pregnancy is a combination of fetal nuchal translucency and evaluation of maternal serum free human Chorionic Gonadotropin (β-hCG) and Pregnancy Associated Plasma Protein A (PAPP-A) through 9-14 weeks of gestation (1, 2). Furthermore, PAPP-A and β-hCG are suggested to be able to predict some pregnancy complications and some previous researchers have tried to evaluate their predicting value (3, 4).

Several studies have suggested that lower serum levels of PAPP-A in the first trimester is associated with more risk of developing pregnancy complications such as low birth weight (5), preterm labor (6), still birth (7), abortion (8), and pregnancy induced hypertension (9). Similar association has been evaluated between pregnancy complications and decreased serum level of β-hCG, however the only
suggested association was found for higher risk of developing abortion in these patients (10).

Despite all these findings, there is still conflicting data on this issue in the literature (1, 4). Previous studies have limitations such as small sample sizes, presence of multiple cofounders, and incomplete exclusion criterion which makes the results unreliable. Also, most studies were conducted in developed countries, specifically European and American countries. To eliminate these limitations, we decided to design a study with a large sample size, determine rigid inclusion and exclusion criterion to eliminate any confounding factor, and follow subjects closely looking for pregnancy complications. To our knowledge, this is the first study performed in Iran and surrounding countries in Middle East on this topic. In this study we evaluate the possible association between maternal serum levels of PAPP-A and free β-hCG and some pregnancy complications.

Materials and methods

This is a case control study which was performed during 2015 to 2016 in two obstetrics and gynecology centers (Alzahra hospital and Shahid Beheshti hospital) affiliated to Isfahan University of Medical Sciences and located in the city of Isfahan, Iran. Pregnant women with the following criteria were invited to enter the study: women who were experiencing their first pregnancy; body mass index (BMI) in the normal range (18.5-24.9). Among them, those with the following characteristics were excluded: taking immunosuppressive, corticosteroid, or thyroid hormones medication; current or previous smoking; diabetes; hypertension; and having anomalies. Also, patients were asked to deliver at our institution to be included in the study. The study was approved by the regional bioethics committee of Isfahan University of Medical Sciences (approval code: 394024) and all patients were asked to fill informed consent before entering the study.

To calculate the sample size, we used the following equation: 

\[ n = \frac{2\left(Z_{\alpha/2}\right)^2P(1-P)}{d^2} \]

\( \alpha \) or Type 1 error was assumed 0.05, \( P \) was adopted from the decreased amount of PAPP-A or β-hCG and was assumed 0.5 to reach the largest possible amount of sample size, and \( d \) was the estimation error which was assumed 0.03. The sample size was calculated to be 1067 after placement of numbers.

Blood samples were taken between 9-14 weeks of gestation to measure maternal serum PAPP-A and free β-hCG using Cobas E 411 analyzer (made by Roche company, Germany, 2011). Patients were observed then till the end of pregnancy and 24 hours after that for possible complications including preterm labor (spontaneous delivery before 37th week of gestation), pregnancy induced hypertension (systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90, recorded more than 1 time), abortion (delivery of dead fetus before 20th week of gestation), and intra-uterine growth retardation (IUGR) (fetus estimated weight under 10 percentile based on ultrasound examination. It should be noted that these outcomes were investigated separately in each patient.

To find the association between maternal serum levels of PAPP-A and free β-hCG, and pregnancy complications we compared means of PAPP-A and β-hCG between groups of cases who developed complications and those experiencing no complications. Also, serum levels of PAPP-A and β-hCG were classified into two groups of normal range (PAPP-A ≥ 0.4 and β-hCG ≥ 0.5) and abnormal range (PAPP-A < 0.4 and β-hCG < 0.5) and the frequency of each group was compared among patients with and without pregnancy complications. It should be noted that these cutoffs were adopted from laboratory classic reference ranges based on multiple of medians of PAPP-A and free β-hCG serum levels in the normal population and after required corrections, and no statistical method was used to determine these cutoffs.

Data were evaluated using Kolmogorov-Smirnov test and the distribution was normal. To analyze and report data, we used descriptive statistics for reporting frequencies and means, and analytical statistics including t-test, chi-square test, ROC curve, and Pearson correlation for statistical analyses using SPSS 20 and the P-value less than 0.05 was considered as significant.

Results

A total 1104 patients entered the study; however 34 of them left the study or did not cooperate for follow-up. Therefore, a total of 1070 patients consisted the study population with the mean age of 28.64 ± 4.95. Descriptive data on PAPP-A and β-hCG serum levels and complications of pregnancy are summarized in Table 1.

Table 2 demonstrates results from comparison of PAPP-A and free β-hCG serum levels between patients with and without complications of pregnancy. We found lower mean serum level of PAPP-A in patients with pregnancy complications, however the
difference was only statistically significant in the category of preterm labor (p = 0.025).

Table 1: Demographic data

| Category     | Subcategory | N    | Range   | Mean ± SD |
|--------------|-------------|------|---------|-----------|
| Age          |             | 1070 | 17-44   | 28.64 ± 4.94 |
| PAPP-A       | < 0.4       | 1070 | 0.22-6  | 1.26 ± 0.58 |
|              | ≥ 0.4       | 23   |         |           |
|              |             | 1047 |         |           |
| B-HCG        | < 0.5       | 1070 | 0.22-9.43 | 1.51 ± 1.04 |
|              | ≥ 0.5       | 72   |         |           |
|              |             | 998  |         |           |
| IUGR         | No          | 1053 |         |           |
|              | Yes         | 17   |         |           |
| Preterm Labor| No          | 1046 |         |           |
|              | Yes         | 24   |         |           |
| HTN          | No          | 1024 |         |           |
|              | Yes         | 46   |         |           |
| Abortion     | No          | 1067 |         |           |
|              | Yes         | 3    |         |           |

SD: Standard deviation; IUGR: Intra-uterine growth retardation; HTN: pregnancy induced hypertension; PAPP-A: pregnancy associated plasma protein A; b-hcg: b human chorionic gonatitropin

Also, the mean serum level of free β-hCG was seen to be lower in patients with pregnancy complications (except those with IUGR), although none of the differences were statistically significant (p > 0.05).

As we mentioned before, we also used cutoff points for PAPP-A and β-hCG to categorize them into two groups of low and normal range, and compared the frequency of each group between patients with and without pregnancy complications. These results are shown in Table 3. PAPP-A < 0.4 was more frequent in patients who developed IUGR, preterm labor, and pregnancy induced hypertension (17.4% versus 1.2%, P<0.001; 13% versus 2%, p = 0.013; and 17.4% versus 4%, p = 0.015 respectively). On the other hand, the frequency of β-hCG < 0.5 and β-hCG ≥ 0.5 among patients with and without pregnancy complications showed a non-significant difference between any of the groups (p > 0.05). It is noteworthy that results from abortion can’t be judged because of very small number of cases in this group. Pearson correlation showed a direct relationship between β-hCG and PAPP-A (r = 0.195, p-value < 0.001).

Table 2: Comparison of PAPP-A and B-HCG means between complications of pregnancy

| Category     | PAPP-A (mean (SD)) | P-value | B-HCG (mean (SD)) | P-value |
|--------------|--------------------|---------|-------------------|---------|
| IUGR         | Yes                | 1.07 (0.57) | 0.184             | 1.52 (1.22) | 0.981 |
|              | No                 | 1.26 (0.58) |                  | 1.51 (1.03) |
| Preterm labor| Yes                | 1.02 (0.48) | 0.025             | 1.23 (0.69) | 0.058 |
|              | No                 | 1.26 (0.58) |                  | 1.52 (1.04) |
| HTN          | Yes                | 1.21 (0.69) | 0.647             | 1.40 (1)    | 0.443 |
|              | No                 | 1.26 (0.58) |                  | 1.52 (1.04) |
| Abortion     | Yes                | 0.75 (0.46) | 0.193             | 0.86 (0.90) | 0.334 |
|              | No                 | 1.26 (0.58) |                  | 1.51 (1.04) |

Discussion

In this study we evaluated the association between decreased maternal serum levels of PAPP-A and free β-hCG, and some pregnancy complications (IUGR, preterm labor, pregnancy induced hypertension, and abortion).

PAPP-A is chorionic product which is released in maternal blood during pregnancy. This protein increases in maternal serum during pregnancy and decreases rapidly after delivery (11).
studies have reported no association and without pregnancy induced hypertension, the no difference between mean PAPP
explain why PAPP
pregnancy induced hypertension have been developing pregnancy induced hypertension have been
levels of PAPP
levels of PAPP
chance of preterm delivery (10, 17). In this
developing IUGR, the frequency of low range PAPP
significant mean PAPP
levels and preterm labor is conflicting in the literature
between PAPP
levels and risk of low birth weight (15). Although we found lower but not
A serum levels and risk of low birth
A may be associated with
A in serum of patients
A may show inadequate
growth retardation; HTN: pregnancy induced hypertension; OR: Odds ratio; CI: Confidence interval
A in patients who developed miscarriage. Also, the frequency of PAPP-A in the abnormal range was smaller in patients developing miscarriage, but still statistically non-significant. Therefore, our results don’t confirm previous findings on the association of decreased PAPP-A serum levels and miscarriage, however, considering the very small number of miscarriage cases in our study, our results on this category may not be reliable.

β-hCG is a hormone excreted from chorionic villus syncytiotrophoblast during pregnancy, and induces progesterone release by stimulating receptors of luteinizing hormone and hCG in corpus luteum (21). Maternal serum free β-hCG is measured for various clinical reasons such as diagnosis of pregnancy, some pregnancy complications, screening chromosomal abnormalities, and screening gynecological cancers (22).

The predicting role of serum free β-hCG in the first trimester for pregnancy complications is studied before, but few of them have suggested such associations between low serum free β-hCG and pregnancy complications (10). In a study researchers measured serum levels of free β-hCG in 10-14 weeks of gestation in 5584 patients and followed them until

### Table 3: Comparison of frequency of pregnancy complications between cutoff points of PAPP-A and B-HCG

| Category       | PAPP-A < 0.4 | PAPP-A ≥ 0.4 | P-value | OR   | CI    | B-HCG < 0.5 | B-HCG ≥ 0.5 | P-value | OR   | CI    |
|----------------|--------------|--------------|---------|------|-------|-------------|-------------|---------|------|-------|
| IUGR Yes       | 4 (17.4%)    | 13 (1.2%)    | < 0.001 | 16.74 | 4.99  | 1 (1.4%)    | 16 (1.6%)   | 0.681   | 0.864| 0.11  |
|                | 19 (82.6%)   | 1034 (98.8%) |         |      | 56.10 | 71 (98.6%)  | 982 (98.4%) | 6.61    |
| Preterm labor  | 3 (13%)      | 21 (2%)      | 0.013   | 7.32 | 2.02  | 3 (4.2%)    | 21 (2.1%)   | 0.215   | 2.02  | 0.58  |
|                | 20 (87%)     | 1026 (98%)   |         |      | 26.57 | 69 (95.8%)  | 977 (97.9%) | 6.94    |
| HTN Yes        | 4 (17.4%)    | 42 (4%)      | 0.015   | 5.03 | 1.64  | 6 (8.3%)    | 40 (4%)     | 0.082   | 2.17  | 0.89  |
|                | 19 (82.6%)   | 1005 (96%)   |         |      | 15.46 | 66 (91.7%)  | 958 (96%)   | 5.32    |
| Abortion Yes   | 1 (4.3%)     | 2 (0.2%)     | 0.063   | 23.75| 2.07  | 2 (2.8%)    | 1 (0.1%)    | 0.013   | 28.46| 2.55  |
|                | 22 (95.7%)   | 1045 (99.8%) |         |      | 271.75| 70 (97.2%)  | 997 (99.9%) | 318     |

PAPP-A: Pregnancy associated plasma protein A; B-HCG: B human chorionic gonadotrophin; SD: Standard deviation; IUGR: intra-uterine growth retardation; HTN: pregnancy induced hypertension; OR: Odds ratio; CI: Confidence interval

This factor is used routinely for screening of Down syndrome during the first trimester and its decreased serum levels can show evidences of chromosomal abnormalities (11). The predicting value of PAPP-A for pregnancy complications has been addressed in several studies before (12). Previous studies have addressed low birth weight to be more associated with low maternal serum PAPP-A (13, 14). In spite of all that, some studies have reported no association between PAPP-A serum levels and risk of low birth weight (15). Although we found lower but not significant mean PAPP-A in serum of patients developing IUGR, the frequency of low range PAPP-A was significantly higher in these patients.

Data on the relationship between PAPP-A serum levels and preterm labor is conflicting in the literature (1, 16), however few studies have drawn an association between low maternal serum PAPP-A and chance of preterm delivery (10, 17). In this study, we found that mean serum levels of PAP-A is lower in patients who experienced preterm delivery later (1.02 versus 1.26). Also, the frequency of serum levels of PAPP-A in low range was significantly higher among patients who developed preterm labor.

Decreased serum levels of PAPP-A in patients developing pregnancy induced hypertension have been reported in several studies previously (13, 17, 18). Low serum levels of PAPP-A may show inadequate or impaired placentation which leads to developing pregnancy induced hypertension (19). This can explain why PAPP-A may be associated with pregnancy induced hypertension. Although we found no difference between mean PAPP-A in patients with and without pregnancy induced hypertension, the frequency of low range PAPP-A was higher in patients developing pregnancy induced hypertension.

Ghasemi-Tehrani et al.
Predicting Pregnancy Complications

the end of pregnancy. They found approximately 15% of patients who experienced abortion, hypertension, growth disorder, and gestational diabetes had serum free β-hCG levels below 10 percentile suggesting that β-hCG is associated with pregnancy complications (1).

Another study evaluated 34271 patients in 10-14 weeks of pregnancy for PAPP-A and β-hCG serum levels and nuchal translucency. They found that patients with free β-hCG serum levels under 1 percentile developed abortion more in < 24 weeks (17). Furthermore, a recent study on 427 patients showed no association between serum levels of PAPP-A and β-hCG in the first trimester and pregnancy complications suggesting that these factors are not associated with pregnancy complications (23).

We found no statistically significant difference between the average of maternal serum free β-hCG between patients with and without pregnancy complications, however these results were close to significant levels for preterm labor. Moreover, comparing the frequency of low range and normal range β-hCG between pregnancy complications resulted in no significant finding, except for abortion. In spite of all that, because of the small number of patients with miscarriage this finding can’t be judged. Therefore, our results suggest no association between β-hCG and pregnancy complications, except for abortion, which needs to be investigated on more patients.

In this study we had some limitations that should be mentioned. First, considering the small number of abortions, we would have more precise results if we enrolled larger number of cases in the study. Second, we evaluated four pregnancy complications, limiting our findings to these complications only. Third, this study was designed as a case-control study, which has its own limitations and biases.

To conclude, PAPP-A and β-hCG are measured in many pregnant women in the first trimester for evaluation of possible chromosomal disorders. Therefore, investigating their association with pregnancy complications is beneficial. In this study we found that low serum levels of PAPP-A are associated with developing IUGR, preterm labor, and pregnancy induced hypertension, however, low serum free β-hCG may be associated with abortion only.

Conflict of Interests
Authors have no conflict of interests.

Acknowledgments
This study was a thesis for obtaining M.D. degree of Dr. Arezoo Sadeghian. We want to thank Isfahan University of Medical Sciences for supporting and funding this project [grant number:394024].

References
1. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotropin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265-70.
2. Huang S, Chang C, Cheng P, Hsiao C, Soong Y, Duan T. First-Trimester Combined Screening Is Effective for the Detection of Unbalanced Chromosomal Translocations at 11 to 12 Weeks of Gestation. Reprod Sci 2014;21:594-600.
3. Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Pergament E, et al. Pregnancy-associated plasma protein A, free β-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004;104:30-6.
4. Sharp AN, Alfirevic Z. First trimester screening can predict adverse pregnancy outcomes. Prenat Diagn 2014;34:660-7.
5. Canini S, Prefumo F, Pastorino D, Crocetti L, Afflitto CG, Venturini PL, et al. Association between birth weight and first-trimester free β–human chorionic gonadotropin and pregnancy–associated plasma protein A. Fertil Steril 2008;89:174-8.
6. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption. Eur J Obstet Gynecol Reprod Biol 2011;157:48-52.
7. Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, et al. Pregnancy–associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 2006;107:161-6.
8. Savvidou M, Syngelaki A, Muhasilen M, Emeleyeneko E, Nicolaides K. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus. BJOG 2012;119:410-6.
9. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first-trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002;22:778-82.
10. Cuckle H, Arbuzova S, Spencer K, Crossley J, Barkai G, Krantz D, et al. Frequency and clinical consequences of extremely high maternal serum PAPPA levels. Prenat Diagn 2003;23:385-8.
11. Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem 2014;63:169-209.
12. Wells G, Bleicher K, Han X, McShane M, Chan YF, Bartlett A, et al. Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A. J Clin Endocrinol Metab 2015;100:2372-9.
13. Nese Kavak Z, Basgul A, Elter K, Uygur M, Gokaslan H. The efficacy of first-trimester PAPP-A and free βhCG levels for predicting adverse pregnancy outcome. J Prenat Med 2006;34:145-8.
14. Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-beta hCG, PAPP-A and inhibin-A. Prenat Diagn 2003;23:990-6.
15. Morssink L, Kornman L, Hallahan T, Kloosterman M, Beehkus J, De Wolf B, et al. Maternal serum levels of free βhCG and PAPPA in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998;18:147-52.
16. Patil M, Panchanadikar T, Wagh G. Variation of papp-A level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India 2014;64:116-9.
17. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
18. Meloni P, D’Angeli I, Piazze J, Cerekya A, Simari T, Pala A, et al. First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension. Hypertens Pregnancy 2009;28:361-8.
19. Khong T, Wolf Fd, Robertson W, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-59.
20. Sonek J, Krantz D, Carmichael J, Downing C, Jessup K, Haidar Z, et al. First trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume. Am J Obstet Gynecol 2017.pii: S0002-9378(17)31217-6.
21. Talmadge K, Vanvakopoulos NC, Fiddes JC. Evolution of the genes for the β subunits of human chorionic gonadotropin and luteinizing hormone. Nature 1984;307:37-40.
22. Stenman U-H, Tiitinen A, Alflthan H, Valmu L. The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update 2006;12:769-84.
23. Prior T, Mullins E, Bennett P, Kumar S. Are 1st-trimester β-human chorionic gonadotrophin and pregnancy-associated plasma protein A levels predictive of intrapartum fetal compromise in a selected normal population? Aust N Z J Obstet Gynaecol 2014;54:418-23.

Citation: Ghasemi-Tehrani H, Sadeghian A, Entezari R. Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-β-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women. J Fam Reprod Health 2017; 11(4): 219-24.